ArriVent BioPharma Common Net Income
| AVBP Stock | 21.09 0.30 1.40% |
As of the 10th of February, ArriVent BioPharma shows the Mean Deviation of 2.88, downside deviation of 3.12, and Risk Adjusted Performance of 0.0658. ArriVent BioPharma Common technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Analyzing historical trends in various income statement and balance sheet accounts from ArriVent BioPharma's financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ArriVent BioPharma's valuation are summarized below:There are currently one hundred fundamental signals for ArriVent BioPharma Common that can be evaluated and compared over time across rivals. Investors and active traders are advised to validate ArriVent BioPharma's prevailing fundamental performance against the performance between 2010 and 2026 to make sure the trends are evolving in the right direction. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -72.4 M | -76.1 M | |
| Net Loss | -72.4 M | -76.1 M | |
| Net Loss | (2.30) | (2.42) |
ArriVent | Net Income | Build AI portfolio with ArriVent Stock |
Evaluating ArriVent BioPharma's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into ArriVent BioPharma Common's fundamental strength.
Latest ArriVent BioPharma's Net Income Growth Pattern
Below is the plot of the Net Income of ArriVent BioPharma Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in ArriVent BioPharma Common financial statement analysis. It represents the amount of money remaining after all of ArriVent BioPharma Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is ArriVent BioPharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ArriVent BioPharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (80.49 M) | 10 Years Trend |
|
Net Income |
| Timeline |
ArriVent Net Income Regression Statistics
| Arithmetic Mean | (57,845,962) | |
| Coefficient Of Variation | (21.90) | |
| Mean Deviation | 10,538,770 | |
| Median | (51,606,000) | |
| Standard Deviation | 12,670,887 | |
| Sample Variance | 160.6T | |
| Range | 43.6M | |
| R-Value | (0.67) | |
| Mean Square Error | 94.4T | |
| R-Squared | 0.45 | |
| Significance | 0 | |
| Slope | (1,681,333) | |
| Total Sum of Squares | 2568.8T |
ArriVent Net Income History
Other Fundumenentals of ArriVent BioPharma Common
ArriVent Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for ArriVent BioPharma is extremely important. It helps to project a fair market value of ArriVent Stock properly, considering its historical fundamentals such as Net Income. Since ArriVent BioPharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ArriVent BioPharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ArriVent BioPharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Can Biotechnology industry sustain growth momentum? Does ArriVent have expansion opportunities? Factors like these will boost the valuation of ArriVent BioPharma. If investors know ArriVent will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating ArriVent BioPharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
ArriVent BioPharma Common's market price often diverges from its book value, the accounting figure shown on ArriVent's balance sheet. Smart investors calculate ArriVent BioPharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since ArriVent BioPharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ArriVent BioPharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ArriVent BioPharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ArriVent BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
ArriVent BioPharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to ArriVent BioPharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of ArriVent BioPharma.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in ArriVent BioPharma on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding ArriVent BioPharma Common or generate 0.0% return on investment in ArriVent BioPharma over 90 days. ArriVent BioPharma is related to or competes with MeiraGTx Holdings, Replimune, MBX Biosciences, Ginkgo Bioworks, Iovance Biotherapeutics, Valneva SE, and Erasca. ArriVent BioPharma is entity of United States More
ArriVent BioPharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure ArriVent BioPharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess ArriVent BioPharma Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.12 | |||
| Information Ratio | 0.0461 | |||
| Maximum Drawdown | 18.12 | |||
| Value At Risk | (4.81) | |||
| Potential Upside | 6.71 |
ArriVent BioPharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for ArriVent BioPharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as ArriVent BioPharma's standard deviation. In reality, there are many statistical measures that can use ArriVent BioPharma historical prices to predict the future ArriVent BioPharma's volatility.| Risk Adjusted Performance | 0.0658 | |||
| Jensen Alpha | 0.1902 | |||
| Total Risk Alpha | (0.15) | |||
| Sortino Ratio | 0.0556 | |||
| Treynor Ratio | 0.3229 |
ArriVent BioPharma February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0658 | |||
| Market Risk Adjusted Performance | 0.3329 | |||
| Mean Deviation | 2.88 | |||
| Semi Deviation | 2.95 | |||
| Downside Deviation | 3.12 | |||
| Coefficient Of Variation | 1383.64 | |||
| Standard Deviation | 3.76 | |||
| Variance | 14.15 | |||
| Information Ratio | 0.0461 | |||
| Jensen Alpha | 0.1902 | |||
| Total Risk Alpha | (0.15) | |||
| Sortino Ratio | 0.0556 | |||
| Treynor Ratio | 0.3229 | |||
| Maximum Drawdown | 18.12 | |||
| Value At Risk | (4.81) | |||
| Potential Upside | 6.71 | |||
| Downside Variance | 9.74 | |||
| Semi Variance | 8.69 | |||
| Expected Short fall | (3.67) | |||
| Skewness | 0.4743 | |||
| Kurtosis | 0.4323 |
ArriVent BioPharma Common Backtested Returns
Currently, ArriVent BioPharma Common is not too volatile. ArriVent BioPharma Common secures Sharpe Ratio (or Efficiency) of 0.0368, which signifies that the company had a 0.0368 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for ArriVent BioPharma Common, which you can use to evaluate the volatility of the firm. Please confirm ArriVent BioPharma's Risk Adjusted Performance of 0.0658, mean deviation of 2.88, and Downside Deviation of 3.12 to double-check if the risk estimate we provide is consistent with the expected return of 0.14%. ArriVent BioPharma has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.81, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, ArriVent BioPharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding ArriVent BioPharma is expected to be smaller as well. ArriVent BioPharma Common right now shows a risk of 3.81%. Please confirm ArriVent BioPharma Common maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to decide if ArriVent BioPharma Common will be following its price patterns.
Auto-correlation | 0.86 |
Very good predictability
ArriVent BioPharma Common has very good predictability. Overlapping area represents the amount of predictability between ArriVent BioPharma time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of ArriVent BioPharma Common price movement. The serial correlation of 0.86 indicates that approximately 86.0% of current ArriVent BioPharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.86 | |
| Spearman Rank Test | 0.51 | |
| Residual Average | 0.0 | |
| Price Variance | 1.88 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
ArriVent Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, ArriVent BioPharma Common reported net income of (80.49 Million). This is 123.58% lower than that of the Biotechnology sector and 214.91% lower than that of the Health Care industry. The net income for all United States stocks is 114.1% higher than that of the company.
ArriVent Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ArriVent BioPharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ArriVent BioPharma could also be used in its relative valuation, which is a method of valuing ArriVent BioPharma by comparing valuation metrics of similar companies.ArriVent BioPharma is currently under evaluation in net income category among its peers.
ArriVent BioPharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, ArriVent BioPharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to ArriVent BioPharma's managers, analysts, and investors.Environmental | Governance | Social |
ArriVent Fundamentals
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 602.2 M | ||||
| Shares Outstanding | 41.28 M | ||||
| Shares Owned By Insiders | 3.12 % | ||||
| Shares Owned By Institutions | 98.97 % | ||||
| Number Of Shares Shorted | 7.18 M | ||||
| Price To Book | 2.96 X | ||||
| EBITDA | (80.49 M) | ||||
| Net Income | (80.49 M) | ||||
| Total Debt | 176 K | ||||
| Book Value Per Share | 7.47 X | ||||
| Cash Flow From Operations | (70.21 M) | ||||
| Short Ratio | 16.23 X | ||||
| Earnings Per Share | (4.15) X | ||||
| Target Price | 40.23 | ||||
| Number Of Employees | 52 | ||||
| Beta | 1.03 | ||||
| Market Capitalization | 902.41 M | ||||
| Total Asset | 274.94 M | ||||
| Retained Earnings | (238.33 M) | ||||
| Working Capital | 209.71 M | ||||
| Net Asset | 274.94 M |
About ArriVent BioPharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ArriVent BioPharma Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ArriVent BioPharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ArriVent BioPharma Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ArriVent BioPharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ArriVent BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ArriVent BioPharma will appreciate offsetting losses from the drop in the long position's value.Moving together with ArriVent Stock
Moving against ArriVent Stock
The ability to find closely correlated positions to ArriVent BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ArriVent BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ArriVent BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ArriVent BioPharma Common to buy it.
The correlation of ArriVent BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ArriVent BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ArriVent BioPharma Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ArriVent BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma's price analysis, check to measure ArriVent BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma is operating at the current time. Most of ArriVent BioPharma's value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma's price. Additionally, you may evaluate how the addition of ArriVent BioPharma to your portfolios can decrease your overall portfolio volatility.